-
1دورية أكاديمية
المؤلفون: Albert Garcia-Romeu, Joshua Elmore, Rhiannon E. Mayhugh, Nicolas J. Schlienz, Erin L. Martin, Justin C. Strickland, Marcel Bonn-Miller, Heather Jackson, Ryan Vandrey
المصدر: Frontiers in Pharmacology, Vol 13 (2022)
مصطلحات موضوعية: cannabis (marijuana), CBD-cannabidiol, THC-tetrahydrocannabinol, medical marijuana, qualitative, Therapeutics. Pharmacology, RM1-950
الوصف: Aim: To characterize perceived benefits and challenges experienced by medicinal cannabis users.Methods: An anonymous online survey collected demographics, health information, and open-ended responses from medicinal cannabis users regarding perceptions, motivations, and experience of treatment. Qualitative open-ended responses were thematically analyzed.Results: Respondents (N = 808) were predominantly White (79%), female (63%), with a mean (SD) age of 38 (20). Two hundred eighty-four (35%) respondents provided data on a dependent family member (e.g., child; 22% of total sample). Most used cannabidiol (CBD)-dominant products (58%), primarily for neurological disorders (38%) or pain (25%). Primary motivations for medicinal cannabis use were based on beliefs that traditional treatments were ineffective and/or had intolerable side effects (51%), positive scientific or media portrayals of the safety/efficacy of cannabis as a therapeutic (29%), or preference for “natural” treatments over pharmaceuticals (21%). A majority of respondents (77%) attributed positive effects to the medicinal use of cannabis/cannabinoids. These included physical symptom improvements such as reduced pain (28%), improved sleep (18%), and seizure reduction (18%), and mental health improvements including reduced anxiety (22%) and improved mood (11%). Additionally, respondents reported reduced use of other medications (e.g., opioids) (12%), and improved quality of life (14%). Problems associated with use were cited by 41% of respondents, and included unwanted side effects (16%), lack of information or medical support (16%), prohibitive costs (12%), and legal concerns (10%).Conclusion: Most participants reported benefits from cannabis use for a variety of conditions where traditional treatments were ineffective or unacceptable. Concerns regarding cannabis side effects, legality, lack of information, and cost were raised. Data indicate greater research and education on the safety and efficacy of medicinal cannabis/cannabinoid use is warranted.
وصف الملف: electronic resource
العلاقة: https://www.frontiersin.org/articles/10.3389/fphar.2022.965535/fullTest; https://doaj.org/toc/1663-9812Test
-
2دورية أكاديمية
المؤلفون: Erin L. Martin, Justin C. Strickland, Nicolas J. Schlienz, Joel Munson, Heather Jackson, Marcel O. Bonn-Miller, Ryan Vandrey
المصدر: Frontiers in Psychiatry, Vol 12 (2021)
مصطلحات موضوعية: anxiety, depression, cannabis, CBD-cannabidiol, THC-tetrahydrocannabinol, Psychiatry, RC435-571
الوصف: Background: Anxiety and depressive disorders are highly prevalent. Patients are increasingly using medicinal cannabis products to treat these disorders, but little is known about the effects of medicinal cannabis use on symptoms of anxiety and depression. The aim of the present observational study was to assess general health in medicinal cannabis users and non-using controls with anxiety and/or depression.Methods: Participants (368 Cannabis Users; 170 Controls) completed an online survey assessing anxiety and depressive symptoms, cannabis product use, sleep, quality of life, and comorbid chronic pain. Participants that completed this baseline survey were then invited to complete additional follow-up surveys at 3-month intervals. Baseline differences between Cannabis Users and Controls were assessed using independent-samples t-tests and generalized linear mixed effects models were used to assess the impact of initiating cannabis product use, sustained use, or discontinuation of use on anxiety and depressive symptoms at follow-up.Results: Medicinal cannabis use was associated with lower self-reported depression, but not anxiety, at baseline. Medicinal cannabis users also reported superior sleep, quality of life, and less pain on average. Initiation of medicinal cannabis during the follow-up period was associated with significantly decreased anxiety and depressive symptoms, an effect that was not observed in Controls that never initiated cannabis use.Conclusions: Medicinal cannabis use may reduce anxiety and depressive symptoms in clinically anxious and depressed populations. Future placebo-controlled studies are necessary to replicate these findings and to determine the route of administration, dose, and product formulation characteristics to optimize clinical outcomes.
وصف الملف: electronic resource
العلاقة: https://www.frontiersin.org/articles/10.3389/fpsyt.2021.729800/fullTest; https://doaj.org/toc/1664-0640Test
النص الكامل